Even though it reduces belly fat, the injection doesn’t make blood sugar worse or cause diabetes in these patients.
Scientific Claim
Tesamorelin (2 mg subcutaneous daily for 6–12 months) does not significantly alter glucose metabolism parameters in HIV-infected adults on antiretroviral therapy with abdominal fat accumulation, indicating no adverse metabolic effect.
Original Statement
“Insulin-like growth factor-1 increased (P < 0.001), but no change in glucose parameters was observed.”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
definitive
Can make definitive causal claims
Assessment Explanation
The RCT design with direct measurement of glucose parameters and lack of significant change supports definitive language for absence of effect.
Evidence from Studies
Supporting (1)
Unknown Title
The study found that even though tesamorelin reduced belly fat in HIV patients, it didn’t make their blood sugar levels worse or better — so it’s safe for metabolism.